Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer

Abstract

Alternating sequential palbociclib/paclitaxel in patients with Rb⁺ advanced breast cancer is feasible and safe, without evidence of additive toxicity. This represents a new application for CDK 4/6 inhibitors in Rb⁺ breast cancer regardless of subtype; efficacy trials are warranted.